Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients
Data published in the British Journal of Clinical Pharmacology demonstrate that PUR0200 achieves similar improvements in lung function to Spiriva® HandiHaler® at significantly lower doses
Page (1) of 1 - 06/13/18||
(June 13, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved